Mitoxantrone treatment in advanced breast cancer.
Aust N Z J Surg
; 54(1): 21-4, 1984 Feb.
Article
en En
| MEDLINE
| ID: mdl-6372775
ABSTRACT
Half of our patients presenting with breast cancer will eventually require cytotoxic chemotherapy. In searching for an effective drug with low toxicity, many new drugs have been investigated. Seventeen patients with advanced breast cancer were treated with mitoxantrone, an analogue of adriamycin. The response rate was 44% (CR 6% + PR 38%). Side effects were fewer than those normally anticipated for most cytotoxic chemotherapy in that only two patients suffered hair loss and three nausea and vomiting. There was, however, significant bone marrow depression with granulocytopenia and two patients died of septicaemia following treatment. Cardiac toxicity occurred in two patients of these, both had prior treatment with adriamycin, and one had prior radiotherapy to the chest wall. Both of these patients died.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Antraquinonas
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Aust N Z J Surg
Año:
1984
Tipo del documento:
Article